{"product_id":"9780792387596","title":"Falk Symposium","description":"\u003ch1\u003eFalk Symposium\u003c\/h1\u003e \u003ch2\u003eManns, M.P.; Paumgartner, G.; Leuschner, U.\u003c\/h2\u003e \u003cp\u003eIn 1992, the Falk Symposium No. 70 dealt with the topic  `Immunology and Liver'. At that time basic mechanisms of immunology as  well as immunopathogenetic mechanisms in viral and autoimmune liver  diseases were discussed. Now, 7 years later, the Falk Symposium No.  114, held in Basel, Switzerland, October 20-21 1999 (Part I of the  Basel Liver Week 1999), focused on immunology in autoimmune liver  diseases. In the first section basic mechanisms of autoimmunity are  presented, including the relevance of superantigens and the role of  apoptosis. A further topic is the latest developments concerning  animal models for autoimmune diseases. Recently the International  Autoimmune Hepatitis Group newly defined and reclassified the syndrome  of autoimmune hepatitis. Autoimmune hepatitis is now identified and  studied in all parts of the world, including Asia and South America. A  special variant of autoimmune hepatitis was identified as one organ  manifestation of the autoimmune polyendocrine syndrome type 1, a  genetic disease caused by mutations in a single transcription factor.  Drug- and hepatitis-virus induced immune mediated liver diseases may  serve as models for nonhepatic immune mediated disorders. DNA  technology has increased our knowledge of the immunogenetic background  of autoimmune liver diseases. Among the cholestatic immune mediated  liver diseases, significant progress has been made concerning primary  biliary cirrhosis, in particular regarding the identification of  mitochondrial antigens and the characterisation of the immune  reactions directed at them. The involvement of infectious agents in  PBC as well as the definition of overlap syndromes is a particular  focus for basic and clinical research in this area. \u003cbr\u003e  Concerning the therapy of autoimmune liver diseases, corticosteroids  and azathioprin remain the state of the art for autoimmune hepatitis,  while bile acids have become well established in treatment of primary  biliary cirrhosis as wellas primary sclerosing cholangitis. New drugs  in the future will include topical steroids such as budesonide and new  immunosuppressive agents like mofetil\/mycophenolate. Liver  transplantation is the treatment of choice for end stage liver  diseases; all autoimmune liver diseases are among the best candidates  for liver transplantation. Hopefully, new therapeutic strategies based  on the results obtained from experimental models will become everyday  clinical practice in the next decade. Therefore this symposium  concludes with a discussion.\u003c\/p\u003e \u003ch3\u003eDetails\u003c\/h3\u003e \u003cp\u003ePublished by: Springer\u003c\/p\u003e \u003cp\u003ePublication Date: 2000-08-31\u003c\/p\u003e \u003cp\u003eFormat: Hardcover\u003c\/p\u003e \u003cp\u003eISBN-13: 9780792387596\u003c\/p\u003e \u003cp\u003eDOI: 10.1007\/978-94-011-4000-3\u003c\/p\u003e \u003cp\u003eDimensions: 235cm x155cm\u003c\/p\u003e \u003cp\u003ePages: 400\u003c\/p\u003e ","brand":"Springer Netherlands","offers":[{"title":"Default Title","offer_id":44541624647820,"sku":"9780792387596","price":152.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0710\/9545\/1788\/files\/9780792387596.jpg?v=1771517826","url":"https:\/\/lateknightbooks.com\/products\/9780792387596","provider":"Late Knight Books and Services, LLC","version":"1.0","type":"link"}